Daniel Rabinowitz, serving as the Secretary and Chief Legal Officer for Natera, Inc. (NASDAQ:NTRA), has executed a significant transaction involving the company's equity. On June 24, 2026, Rabinowitz sold a total of 33,600 shares of Natera's common stock. The aggregate value of these shares was approximately $8.45 million. The shares were sold at weighted average prices that ranged between $250.2491 and $253.3884 per share. These transactions were carried out in accordance with a Rule 10b5-1 trading plan. Rabinowitz originally adopted this specific trading plan on December 5, 2025. Following the completion of these sales, Rabinowitz maintains a direct ownership position of 189,094 shares of Natera common stock.
Insider transactions of this nature are often monitored closely as they can provide insight into internal confidence and valuation perceptions. The sale comes at a time when Natera's stock is trading at $261.27. This price point is near the company's 52-week high of $271.47. The stock has experienced a remarkable 56% gain over the past year. According to analysis from InvestingPro, the stock currently appears overvalued relative to its Fair Value. Investors seeking deeper insights can access Natera's comprehensive Pro Research Report, which is available for this and 1,400+ other US equities.
Key Points
- Regulatory Milestone in Japan: Natera Inc. announced that its Signatera test received regulatory approval from Japan’s Pharmaceuticals and Medical Devices Agency. This approval allows the use of Signatera for patients with colorectal cancer in the adjuvant setting. This represents the first PMDA-approved molecular residual disease test in Japan. The company plans to commercially launch Signatera for colorectal cancer in Japan by the end of 2026, pending final pricing determination.
- Clinical Guideline Updates: The National Comprehensive Cancer Network updated its Clinical Practice Guidelines in Oncology for Bladder Cancer. The update recommends the consideration of ctDNA-MRD testing for risk stratification in certain patients. This update specifies the use of an FDA-approved, personalized, tumor-informed, multiplex PCR-NGS assay for ctDNA. BTIG raised its price target on Natera shares to $270, maintaining a Buy rating, after the inclusion of Natera’s Signatera MRD test in the National Comprehensive Cancer Network (NCCN) guidelines for muscle-invasive bladder cancer.
- Analyst Coverage and Market Activity: Bernstein SocGen Group resumed coverage on Natera with an outperform rating and a price target of $310. The firm highlighted the company’s catalyst path to increased volumes and reimbursement in minimal residual disease testing, with Japan expected to serve as a volume driver. Additionally, Natera experienced a notable increase in options trading activity, with a focus on call options.
Risks and Uncertainties
- Pricing and Commercialization Delays: The commercial launch of Signatera for colorectal cancer in Japan is pending final pricing determination. This introduces uncertainty regarding the timeline and potential revenue impact of this new market entry.
- Valuation Concerns: Analysis from InvestingPro indicates that the stock currently appears overvalued relative to its Fair Value. This suggests potential risks for investors who may be exposed to a correction if market perceptions shift.
- Market Volatility: While the stock has seen a 56% gain over the past year, the high level of options trading activity, particularly in call options, may indicate increased volatility. Investors should consider the potential for price fluctuations in the short term.
Natera Inc. (NTRA) is a key player in the molecular diagnostics sector, particularly in the field of minimal residual disease testing. The company's recent regulatory approvals and guideline updates position it for potential growth in the oncology market. However, the insider sale by Rabinowitz and the company's current valuation metrics warrant careful consideration by investors.